Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of “Buy” by Analysts

Guardant Health, Inc. (NASDAQ:GH) has been assigned a consensus recommendation of “Buy” from the sixteen ratings firms that are presently covering the stock, Marketbeat.com reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $42.63.

GH has been the topic of a number of recent analyst reports. The Goldman Sachs Group raised their price target on Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Barclays initiated coverage on Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price on the stock. Sanford C. Bernstein lowered their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Leerink Partners cut their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, Guggenheim restated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd.

Guardant Health Stock Down 0.2 %

NASDAQ:GH opened at $44.40 on Tuesday. The firm has a market capitalization of $5.49 billion, a price-to-earnings ratio of -10.47 and a beta of 1.32. The stock’s 50 day moving average price is $38.30 and its two-hundred day moving average price is $30.74. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89.

Insiders Place Their Bets

In related news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,548 shares of company stock valued at $179,782. 5.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its holdings in shares of Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock valued at $1,089,000 after purchasing an additional 403 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after purchasing an additional 796 shares during the period. Jones Financial Companies Lllp increased its position in shares of Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares in the last quarter. Fiduciary Alliance LLC raised its position in Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock valued at $363,000 after purchasing an additional 836 shares during the period. Finally, R Squared Ltd acquired a new position in Guardant Health during the 4th quarter worth approximately $26,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.